JPH11506340A - アポプチンの利用と方法 - Google Patents
アポプチンの利用と方法Info
- Publication number
- JPH11506340A JPH11506340A JP9500327A JP50032797A JPH11506340A JP H11506340 A JPH11506340 A JP H11506340A JP 9500327 A JP9500327 A JP 9500327A JP 50032797 A JP50032797 A JP 50032797A JP H11506340 A JPH11506340 A JP H11506340A
- Authority
- JP
- Japan
- Prior art keywords
- apoptin
- cells
- apoptosis
- functional equivalent
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Public Health (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Light Receiving Elements (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.トランスフォームされた、および/または悪性、および/または腫瘍細胞 と正常細胞を区別する方法であって、該細胞にウイルス性蛋白質3(VP3;ア ポプチン)を与え、該細胞中の該蛋白質の局在性を測定する工程を含むことを特 徴とする方法。 2.対象となる核酸をターゲット細胞に運搬するための媒介物であって、さら にアポプチンをコードする遺伝子またはその機能的同等物を含むことを特徴とす る媒介物。 3.ターゲット腫瘍治療のための抱合体であって、主に結合する分子に対して 結合親和性を持つが、腫瘍細胞の表面には全く存在しないターゲティング部分と 、アポプチンまたはその機能的同等物を含むことを特徴とする抱合体。 4.腫瘍形成性物質あるいは腫瘍形成性物質をコードする遺伝子を、腫瘍細胞 の表面には全く存在しないが、主に結合する分子に運搬する媒介物であって、該 腫瘍形成物質がアポプチンまたはその機能的同等物であることを特徴とする媒介 物。 5.ターゲット細胞の個体数を低減するための方法に用いるためのアポプチン またはその機能的同等物であって、該方法が主にターゲット細胞に特異的ではあ るが、完全に特異的ではなく、アポプチンまたはその機能的同等物が細胞毒性物 質であることを特徴とするアポプチンまたはその機能的同等物。 6.ターゲット細胞の個体数を低減するための用途に用いるためのアポプチン またはその機能的同等物であって、該細胞が、他のアポトーシス誘発剤に対して 感受性がないことを特徴とするアポプチンまたはその機能的同等物。 7.細胞核局在化シグナルを備えたアポプチンまたはその機能的同等物。 8.ターゲット細胞集合の細胞を除く方法に用いられる請求項8記載のアポプ チンまたはその機能的同等物。 9.請求項8のアポプチンまたはその機能的同等物をコードする核酸。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/484,939 US6319693B1 (en) | 1990-09-12 | 1995-06-07 | Cloning of chicken anemia virus DNA |
US484,939 | 1995-06-07 | ||
PCT/NL1996/000229 WO1996041191A1 (en) | 1995-06-07 | 1996-06-07 | Methods and uses for apoptin |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11506340A true JPH11506340A (ja) | 1999-06-08 |
Family
ID=23926260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9500327A Pending JPH11506340A (ja) | 1995-06-07 | 1996-06-07 | アポプチンの利用と方法 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0830604B1 (ja) |
JP (1) | JPH11506340A (ja) |
AT (1) | ATE241808T1 (ja) |
AU (1) | AU718422B2 (ja) |
CA (1) | CA2221495C (ja) |
DE (1) | DE69628431T2 (ja) |
DK (1) | DK0830604T3 (ja) |
ES (1) | ES2200065T3 (ja) |
NZ (1) | NZ309171A (ja) |
PT (1) | PT830604E (ja) |
WO (1) | WO1996041191A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003516152A (ja) * | 1999-12-10 | 2003-05-13 | レアト ベー.フェー. | アポプチン会合タンパク質 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1188832A1 (en) * | 2000-09-08 | 2002-03-20 | Leadd B.V. | A delivery method for the tumor specific apoptosis inducing activity of apoptin |
KR20010022812A (ko) * | 1997-08-12 | 2001-03-26 | 리드 비.브이. | 인자의 변형능력을 측정하는 방법 |
IL144228A0 (en) * | 1999-01-11 | 2002-05-23 | Leadd Bv | Use of apoptosis inducing agents in the treatment of (auto) immune diseases |
AU2004233486B2 (en) * | 1999-01-11 | 2007-09-13 | Leadd B.V. | Use of apoptosis inducing agents in the treatment of (auto)immune diseases |
DK1083224T3 (da) | 1999-09-02 | 2007-04-10 | Leadd Bv | Apoptin-associerende protein |
EP1186665A1 (en) * | 2000-09-08 | 2002-03-13 | Leadd B.V. | A delivery method for the tumor specific apoptosis inducing activity of apoptin |
AU2001294393A1 (en) * | 2000-09-08 | 2002-03-22 | Leadd B.V. | A delivery method for the tumor specific apoptosis inducing activity of apoptin |
EP1199363A1 (en) * | 2000-10-20 | 2002-04-24 | Leadd B.V. | Phosphorylation modifications of apoptin |
ATE414776T1 (de) * | 2001-03-30 | 2008-12-15 | Leadd Bv | Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten |
WO2002085305A2 (en) * | 2001-04-24 | 2002-10-31 | Washington University | Compositions and methods for inducing cancer cell death |
WO2003089936A1 (en) * | 2002-04-19 | 2003-10-30 | Leadd B.V. | Aberrant-specific pathways |
WO2003089467A1 (en) * | 2002-04-19 | 2003-10-30 | Leadd B.V. | Fragments of apoptin |
US9403880B2 (en) | 2010-11-26 | 2016-08-02 | Institut Pasteur | Identification of a human gyrovirus and applications |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL9301272A (nl) * | 1993-07-20 | 1995-02-16 | Aesculaap Bv | Chicken Anemia Virus mutanten en vaccins en toepassingen gebaseerd op de virale eiwitten VP1, VP2 en VP3 of daarvoor coderende sequenties van dat virus. |
US5981502A (en) * | 1990-09-12 | 1999-11-09 | Leadd B.V. | Methods and compositions for inducing apoptosis in tumor cells |
-
1996
- 1996-06-07 ES ES96916378T patent/ES2200065T3/es not_active Expired - Lifetime
- 1996-06-07 JP JP9500327A patent/JPH11506340A/ja active Pending
- 1996-06-07 EP EP96916378A patent/EP0830604B1/en not_active Expired - Lifetime
- 1996-06-07 CA CA2221495A patent/CA2221495C/en not_active Expired - Fee Related
- 1996-06-07 DK DK96916378T patent/DK0830604T3/da active
- 1996-06-07 DE DE69628431T patent/DE69628431T2/de not_active Expired - Fee Related
- 1996-06-07 AT AT96916378T patent/ATE241808T1/de not_active IP Right Cessation
- 1996-06-07 NZ NZ309171A patent/NZ309171A/xx not_active IP Right Cessation
- 1996-06-07 AU AU59136/96A patent/AU718422B2/en not_active Ceased
- 1996-06-07 PT PT96916378T patent/PT830604E/pt unknown
- 1996-06-07 WO PCT/NL1996/000229 patent/WO1996041191A1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003516152A (ja) * | 1999-12-10 | 2003-05-13 | レアト ベー.フェー. | アポプチン会合タンパク質 |
Also Published As
Publication number | Publication date |
---|---|
ATE241808T1 (de) | 2003-06-15 |
AU718422B2 (en) | 2000-04-13 |
DE69628431T2 (de) | 2004-05-06 |
EP0830604A1 (en) | 1998-03-25 |
CA2221495C (en) | 2010-06-01 |
AU5913696A (en) | 1996-12-30 |
ES2200065T3 (es) | 2004-03-01 |
EP0830604B1 (en) | 2003-05-28 |
CA2221495A1 (en) | 1996-12-19 |
NZ309171A (en) | 2000-04-28 |
PT830604E (pt) | 2003-10-31 |
WO1996041191A1 (en) | 1996-12-19 |
DE69628431D1 (de) | 2003-07-03 |
DK0830604T3 (da) | 2003-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Behrens et al. | Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. | |
JPH11506340A (ja) | アポプチンの利用と方法 | |
Zhuang et al. | Differential sensitivity to Ad5 E1B-21kD and Bcl-2 proteins of apoptin-induced versus p53-induced apoptosis | |
JP4986370B2 (ja) | Rgmおよびそのモジュレーターの用途 | |
Li et al. | Sublytic complement attack exposes C-reactive protein binding sites on cell membranes. | |
Quigg et al. | Decay accelerating factor regulates complement activation on glomerular epithelial cells. | |
JP2003508355A (ja) | 卵巣癌細胞及び骨髄腫細胞の表面糖タンパク質、それへの抗体及びその使用 | |
KR20050110012A (ko) | 노고 수용체 결합 단백질 | |
CA2542171C (en) | Modulators and modulation of the interaction between rgm and neogenin | |
Hochgrebe et al. | A reexamination of the role of clusterin as a complement regulator | |
Inukai et al. | Expression of Fas antigen is not associated with apoptosis in human myopathies | |
WO2004113497A2 (en) | Gene delivery to tumors | |
KR100739118B1 (ko) | Msx1 단백질 또는 이를 코딩하는 유전자의 신규한 용도 | |
EP1004021B1 (en) | Determining the transforming capability of agents | |
EP0878546A1 (en) | A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin | |
Riser et al. | Monocyte killing of human squamous epithelial cells: role for thrombospondin | |
Assmann et al. | The organ distribution of gp-330 (Heymann antigen) and gp-90 in the mouse and the rat | |
Spiller et al. | Complement expression on astrocytes and astrocytoma cell lines: failure of complement regulation at the C3 level correlates with very low CD55 expression | |
RU2252255C2 (ru) | Вектор доставки генов, способный индуцировать апоптоз в клетке | |
EP1143994B1 (en) | Use of apoptosis inducing agents in the preparation of a medicament for the treatment of (auto)immune diseases | |
MXPA97009860A (en) | Methods and uses for apopt | |
Kabakov et al. | LDL-mediated interaction of DNA and DNA-anti-DNA immune complexes with cell surface | |
Lou et al. | E‐, P‐, and N‐cadherin are co‐expressed in the nasopharyngeal carcinoma cell line TW‐039 | |
WO2003089467A1 (en) | Fragments of apoptin | |
US20020045187A1 (en) | Methods and compositions for stimulating the immune system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050830 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051130 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060123 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071113 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080213 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080324 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080313 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080916 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081216 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090511 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090702 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20090709 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100720 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100726 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100820 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100826 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100921 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100927 |